Login to Your Account



Inverseon, CBio Combine Programs in All-Stock Merger

By Marie Powers
Staff Writer

Wednesday, August 29, 2012

Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane.

The merged entity will combine programs from each company to focus broadly on inflammatory disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription